Radiation for Breast Cancer: 603 Real Stories

603 stories match breast cancer and radiation. 562 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

HER2-amplified primary mucinous cystadenocarcinoma of the breast: surgery and adjuvant treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: HER2-amplified / HER2 3+; ER/PR-negative; Ki-67 ~50%; p53 high; microsatellite stable. No clinically significant inherited mutation reported.

As of November 2024, she had more than 104 months of disease-free survival after breast-conserving surgery, sentinel lymph node biopsy, EC-T chemotherapy, and radiotherapy for Stage IIA HER2-amplified primary mucinous cystadenocarcinoma of the breast.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Lung inflammation from pembrolizumab immunotherapy returned months after stopping treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: Estrogen receptor-negative; progesterone receptor-negative; HER2-negative

Surgery confirmed a pathologic complete response, and she remained in breast-cancer remission during routine follow-up after treatment for recurrent pembrolizumab-related pneumonitis.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Inflammatory Breast CancerBreast Cancer

Bilateral inflammatory breast cancer treated with pembrolizumab and surgery

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Bilateral breast cancers had different biology: right side ER/PR-positive and HER2 FISH-negative; left side triple-negative/HER2 1+.

As of March 2025, she had no recurrence 6 months after bilateral mastectomy, bilateral axillary lymph node dissection, thoracoabdominal flap closure, and planned postmastectomy radiation for Stage IIIC bilateral inflammatory breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Breast cancer history: atypical pelvic fracture after long-term zoledronic acid

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Prior breast cancer treatment had been completed; CT during fracture evaluation showed no metastatic disease, and the atypical iliac wing fracture healed progressively with conservative care and teriparatide.

PubMed Central
OutcomeSurvivorship / Completed Treatment
Katie, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Katie's Patient Story

Patient Info: Katie, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; genetic testing negative

As of February 2025, Katie was a few months beyond active treatment for Stage III ER-positive, PR-positive, HER2-negative ILC and was adjusting to maintenance therapy with Verzenio, Lupron, and Letrozole.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
Chance, who was diagnosed with Stage II Breast CancerBreast Cancer

Facing Triple-Negative Breast Cancer: Chance’s Story

Patient Info: Chance, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of February 2025, Chance described follow-up after Stage II BRCA1-associated triple-negative breast cancer and stated that she did not currently have cancer, while continuing close surveillance.

The Patient Story
OutcomeCancer-Free / NED
Kelly, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Triple-Negative Breast Cancer: Kelly's Survivor Story

Patient Info: Kelly, Female, Under 40 | Stage III

Biomarkers: Triple-negative breast cancer; no inherited cancer gene mutation found.

As of February 2025, Kelly identified as a Stage IIIC triple-negative breast cancer survivor after neoadjuvant chemotherapy, double mastectomy with reconstruction, and radiation, and was using her experience to support others through TNBC Thrivers.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Breast Cancer Returning About 20 Years After Initial Treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones

About 20 years after her original breast-cancer treatment and sustained remission, bone biopsy confirmed metastatic recurrence; she became too unwell for planned cancer therapy and chose supportive care.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Breast CancerBreast Cancer

Breast cancer survivor with synchronous intercostal nerve schwannomas mimicking metastasis

Patient Info: Anonymized, Female, Under 40

Biomarkers: Breast cancer biomarkers not reported; schwannomas were S100-positive

After prior breast cancer treatment, later D6-D7/rib lesions were proven to be S100-positive schwannomas rather than metastases, and surgical removal relieved the patient’s rib-cage numbness and pain.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage 4 hormone receptor-positive breast cancer: remission with PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HR-positive breast cancer with HER2-low/negative recurrence, and pathogenic BRCA2 R2318* mutation.

Metastatic Site: pleura

As of January 2025, she had maintained complete response for 36 months after sequential FEC/docetaxel and olaparib for hormone receptor-positive, HER2-negative/HER2-low metastatic breast cancer with BRCA2 R2318* mutation.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I ER-positive/HER2-positive breast cancer with radiation-associated morphea

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER-positive; PR-negative; HER2-positive

No evidence of breast cancer recurrence after 2018 treatment; ongoing issue was generalized morphea and breast deformity related to prior radiation, improved with mycophenolate by April 2024.

PubMed Central
OutcomeCancer-Free / NED
India, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: India's Survivor Story

Patient Info: India Robinson, Female, 40s | Stage II

As of January 2025, India had completed Stage II breast cancer treatment and had returned to work, the gym and daily life after robotic lymphatic microsurgery resolved breast lymphedema; the story does not explicitly state NED.

Cleveland Clinic
OutcomeSurvivorship / Surveillance
MB
Breast Cancer

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Breast CancerBreast Cancer

Prior breast cancer treated with radiation, then radiation-related heart damage

Patient Info: Anonymized, Female, 60s

Breast cancer treatment had been completed 10 years earlier; the case mainly documents successful surgery for radiation-associated coronary and aortic valve disease, with no major cardiac events at 5 years.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage I triple-negative solid basaloid adenoid cystic breast cancer treated with mastectomy and oral chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Current tumor was triple-negative with high Ki-67 and c-kit/CK7 staining. Prior breast cancer was ER-positive, HER2-positive, PR-negative.

One year after mastectomy and postoperative tegafur-gimeracil-oteracil potassium, she was recovering well without signs of metastasis.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-Positive Breast Cancer With Metastatic Progression and Drug-Induced Lupus During T-DM1

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones, axillary lymph nodes, intra-abdominal lymph…

More than 5 years after her March 2018 diagnosis, she was living with metastatic breast cancer, but T-DM1 had been stopped after disease progression in 2023.

PubMed Central
OutcomeSetback / Progression